VolitionRx Limited filings document an operating epigenetics diagnostics company with public-company disclosures centered on Nu.Q® assays, capital structure and exchange compliance. Recent 8-K reports and proxy materials cover shareholder votes on common-stock issuance capacity and reverse-stock-split authority, the effectiveness of a one-for-twenty reverse split, and amendments to the company’s certificate of incorporation.
The filing record also includes material-event reports on NYSE American continued-listing standards, annual financial-result updates, unregistered sales of equity securities, convertible-note share settlements, private placements and warrants. These documents describe governance approvals, security-holder rights, financing mechanics, listing-compliance matters and operating updates for Volition’s diagnostics and monitoring business.
VOLITIONRX LTD President and CEO Cameron John Reynolds reported an equity compensation grant. On February 26, 2026, he was awarded 486,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation.
The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, conditioned on continued service. Once vested and settled, they will convert into an equal number of common shares.
Following this grant, he holds 3,115,547 common shares directly, plus indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.
Batchelor Ann-Louise reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd reported that Group Chief Marketing Officer Ann-Louise Batchelor was granted 142,000 restricted stock units (RSUs) on February 26, 2026 under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation. The RSUs will be earned in twelve roughly equal monthly installments starting March 1, 2026, then vest in a single installment on February 26, 2027, subject to her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU earned and vested. Following these transactions, she also reports indirect ownership of common stock held by her spouse.
Hughes Terig reported acquisition or exercise transactions in this Form 4 filing.
VOLITIONRX LTD Chief Financial Officer Terig Hughes reported an equity compensation grant rather than a market trade. On February 26, 2026, he was awarded 202,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.
The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026. All earned RSUs are then subject to additional time-based vesting in a single installment on February 26, 2027, generally conditioned on Mr. Hughes’ continued service. Upon vesting and settlement, he will receive an equivalent number of common shares.
Rootsaert Rodney Gerard reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd's secretary, Rodney Gerard Rootsaert, reported an equity compensation grant. He was awarded 119,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve roughly equal monthly installments starting on March 1, 2026.
Once earned, all RSUs are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Following this award, he holds 281,262 shares of common stock directly and has indirect ownership of 1,007,718 shares through Concord International, Inc., where he shares voting and dispositive control.
VolitionRx Ltd reported that General Counsel of Volition Diagnostics, Nicholas Plummer, acquired an award linked to 187,000 restricted stock units (RSUs) on common stock under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation otherwise payable to him.
The RSUs are scheduled to be earned in twelve approximately equal monthly installments starting on March 1, 2026, then subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Upon vesting and settlement, he will receive one share of common stock for each earned and vested RSU. Following this award, his directly held common stock position is reported as 420,137 shares.
Nguyen Kim reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd director Kim Nguyen was awarded 178,000 restricted stock units (RSUs) of common stock on February 26, 2026. The award was made under the company’s 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve approximately equal monthly installments beginning February 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, conditioned on continued service. Upon vesting and settlement, Nguyen will receive one share of common stock for each RSU earned and vested. The filing also notes 30,556 shares of common stock held indirectly through Nguyen’s spouse.
Kway Jasmine reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd executive Jasmine Kway reported an equity compensation grant. On February 26, 2026, she was awarded 173,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.
The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, and then are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU that has been earned and vested.
VolitionRx chief scientific officer Jacob Vincent Micallef acquired an award of 149,000 restricted stock units on February 26, 2026 under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in roughly equal monthly installments from March 1, 2026 and remain subject to additional time-based vesting on February 26, 2027, conditioned on continued service. The filing also notes indirect holdings of 55,000 common shares by his spouse and 38,113 common shares held by Borlaug Limited, which he controls.
Innes Guy Archibald reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd director Guy Archibald Innes reported an equity compensation grant. On February 26, 2026 he was awarded 178,000 restricted stock units of common stock under the 2024 Stock Incentive Plan, in lieu of cash compensation.
The RSUs are earned in twelve approximately equal monthly installments starting February 1, 2026 and then vest in a single installment on February 26, 2027, subject to his continued service. Following this award, he directly owns 1,252,967 common shares, and also reports indirect holdings through a family trust, a charitable trust and family members.
VolitionRx Limited reported several recent unregistered equity issuances tied to an existing financing arrangement and a prior private placement. Under a $7,500,000 senior secured convertible promissory note held by Lind Global Asset Management XII LLC, the company issued 1,956,178 shares of common stock on February 17, 2026 to satisfy a $416,666 payment, 2,569,753 shares on January 29, 2026 to satisfy a $583,334 payment, and 1,893,936 shares on January 16, 2026 to satisfy a $416,666 payment. These issuances were made to an existing securityholder without commissions or public offering, relying on Securities Act exemptions. The company also notes a previously reported September 18, 2025 private placement of 483,870 shares of common stock and warrants for up to an additional 483,870 shares at an exercise price of $0.682 per share, sold at a combined price of $0.62 per share and warrant for an aggregate $300,000, with similar private-offering exemptions.